Xiang Qun (Sean) Xie
About Xiang Qun (Sean) Xie
Xiang Qun (Sean) Xie serves as the Associate Dean for PharmacoAnalytics at the University of Pittsburgh School of Pharmacy, where he also holds the position of Tenured Professor and Center Director. He has a strong background in pharmaceutical sciences, with significant contributions to drug design, cannabinoid research, and interdisciplinary collaboration in pharmacology.
Current Role at University of Pittsburgh
Xiang Qun (Sean) Xie serves as the Associate Dean for PharmacoAnalytics at the University of Pittsburgh School of Pharmacy. He has held this position since 2021. In addition to his role as Associate Dean, he is also a tenured professor and Center Director, contributing to the academic and research environment of the institution.
Education and Expertise
Xie earned his Doctor of Medicine (MD) from Second Military Medical University in Shanghai, China, from 1978 to 1982. He then pursued a Ph.D. in Pharmaceutical Sciences at the University of Connecticut School of Pharmacy, completing his studies from 1987 to 1993. He later obtained an Executive Master of Business Administration (MBA) from the University of Connecticut School of Business, studying from 2001 to 2003.
Previous Experience at University of Houston
Before his tenure at the University of Pittsburgh, Xie worked at the University of Houston College of Pharmacy from 2003 to 2006 as an Associate Professor and Center Director. His role involved leading academic initiatives and contributing to the pharmacy education landscape in Houston, Texas.
Research Contributions and Publications
Xie has made significant contributions to the field of pharmaceutical sciences, with over 190 publications in high-impact journals such as CELL, Nature Communications, and Proceedings of the National Academy of Sciences (PNAS). His research includes the development of an AI computational drug design and discovery technology, as well as studies on cannabinoid receptors and drug synergy mechanisms.
Patents and Innovations
Xie holds multiple patents related to his research, including five patents concerning cannabinoid receptor CB2, which have therapeutic implications for conditions such as cocaine-attenuation and kidney fibrosis. He has also developed first-in-class drug molecules and invented targeted drugs for hematopoietic stem cell expansion.